<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Both 2-(4-amino-3-<z:chebi fb="0" ids="52553">methylphenyl</z:chebi>)-5-fluorobenzothiazole (5F-203; NSC 703786) and 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (GW-610; NSC 721648) are antitumor agents with novel mechanism(s) </plain></SENT>
<SENT sid="1" pm="."><plain>Previous studies have indicated that <z:chebi fb="0" ids="4056">cytochrome</z:chebi> (<z:chebi fb="0" ids="38559">CYP</z:chebi>) P450 1A1 is crucial for 5F-203 activity </plain></SENT>
<SENT sid="2" pm="."><plain>In the present study, we investigated the functional role of 2 newly identified <z:chebi fb="0" ids="38559">CYP</z:chebi> P450 enzymes, CYP2S1 and CYP2W1, in mediating antitumor activity of <z:chebi fb="0" ids="45993">benzothiazole</z:chebi> compounds </plain></SENT>
<SENT sid="3" pm="."><plain>We generated isogenic <z:hpo ids='HP_0003002'>breast cancer</z:hpo> (<z:chebi fb="14" ids="32506">MDA</z:chebi>-MB-468, MCF-7) and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>; KM12 and HCC2998) cell lines depleted for CYP1A1, CYP2S1, or CYP2W1 </plain></SENT>
<SENT sid="4" pm="."><plain>The sensitivity of these cells to 5F-203 and GW-610 was then compared with vector control cells </plain></SENT>
<SENT sid="5" pm="."><plain>5F-203 exhibited potent activity against <z:hpo ids='HP_0003002'>breast cancer</z:hpo> cells, whereas GW-610 was effective against both breast and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells </plain></SENT>
<SENT sid="6" pm="."><plain>CYP1A1 was induced in both <z:hpo ids='HP_0003002'>breast cancer</z:hpo> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells, while CYP2S1 and CYP2W1 were selectively induced in <z:hpo ids='HP_0003002'>breast cancer</z:hpo> cells only following treatment with 5F-203 or GW-610 </plain></SENT>
<SENT sid="7" pm="."><plain><z:mpath ids='MPATH_63'>Depletion</z:mpath> of CYP1A1 abrogated the sensitivity of <z:hpo ids='HP_0003002'>breast cancer</z:hpo> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells to 5F-203 and GW-610 </plain></SENT>
<SENT sid="8" pm="."><plain>Although <z:mpath ids='MPATH_63'>depletion</z:mpath> of CYP2S1 sensitized both <z:hpo ids='HP_0003002'>breast cancer</z:hpo> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells toward 5F-203 and GW-610, CYP2W1 knockdown caused marked resistance to GW-610 in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells </plain></SENT>
<SENT sid="9" pm="."><plain>Our results indicate that <z:chebi fb="0" ids="38559">CYP</z:chebi>-P450 isoforms, with the exception of CYP1A1, play an important role in mediating <z:chebi fb="0" ids="45993">benzothiazole</z:chebi> activity </plain></SENT>
<SENT sid="10" pm="."><plain>CYP2S1 appears to be involved in deactivation of <z:chebi fb="0" ids="45993">benzothiazoles</z:chebi>, whereas CYP2W1 is important for bioactivation of GW-610 in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells </plain></SENT>
<SENT sid="11" pm="."><plain>Because CYP2W1 is highly expressed in <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumors</z:e>, GW-610 represents a promising agent for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> therapy </plain></SENT>
</text></document>